摘要
目的探讨β_2-肾上腺素能受体(β_2-AR)基因多态性对本地区哮喘患者沙美特罗替卡松吸入治疗的疗效的影响。方法 2013年12月至2015年9月选取本院呼吸内科收治的84例哮喘急性期患者为哮喘组,患者均行沙美特罗替卡松吸入治疗,另选取80例健康体检者为对照组,采用TaqMan-PCR法测定两组β_2-AR的16位点(A-G)基因多态性,分析β_2-AR基因多态性对哮喘患者沙美特罗替卡松吸入治疗的疗效影响及肺功能的影响。结果与对照组相比,哮喘组β_2-AR16位点中GG型基因及G等位基因频率比例较高(P<0.05)。84例哮喘患者中疗效差组GG型基因及G等位基因频率高于疗效理想组(P<0.05)。哮喘组患者β_2-AR中GG基因型患者治疗后肺活量(VC)、肺总量(TLC)、用力呼气肺活量(FVC)、用力呼气肺活量1秒量(FEV_1)、用力呼气肺活量1秒率(FEV_1/FVC)及一氧化碳弥散量(DLCO)水平低于AA型及AG型,而AA及AG基因型治疗后肺功能指标比较无统计学差异(P>0.05)。结论哮喘患者中β_2-AR的16位点基因多态性可能与本地区哮喘的发生有密切的关系,携带β_2-AR变异等位基因G型可能会影响沙美特罗替卡松吸入治疗的效果。
Objective To investigate the impact of β2-AR gene polymorphism on treatment efficacy of salmeterol fluticasone propionate inhalation for patients with asthma. Methods 84 patients with acute asthma were selected as the asthma group and 80 cases of healthy subjects were selected as the control group from December 2013 to September 2015. The β 2-AR 16 loci （AG） of the two groups were assayed with TaqMan-PCR. The asthma salmeterol fluticasoMe propionate inhalation therapy efficacy and lung function were analyzed. Results The frequency of GG genotype and G allele in β2-AR 16 sites was higher in the asthma group than in the control groups （P 〈0. 05）, and it was higher in the poor efficacy group than in the good efficacy group （P 〈 0. 05）. The levels of vital capacity （ VC）, total lung capacity （TLC）, forced expiratory vital capacity （FVC） , forced expiratory vital capacity 1 second volume （FEVl ） , forced expiratory vital capacity 1 seconds ratio （FEV1/FVC） and carbon monoxide diffusing capacity （DLCO） of GG genotype patients were higher than AA and AG genotypes, but there was no significant difference in pulmonary function after treatment between AA and AG genotypes （P 〉 0. 05 ）. Conclusion The gene polymorphism of β2-AR 16- site may be associated with the incidence of asthma, and G type patients carrying β2-An variant allele may have poor salmeterol fluticasone propionate inhalation therapy effect.
出处
《临床肺科杂志》
2017年第2期310-313,共4页
Journal of Clinical Pulmonary Medicine
